BRIEF-Celator pharmaceuticals announces positive results in patients with flt3 mutation from phase 3 trial in high-risk acute myeloid leukemia
June 14, 2016 at 07:09 AM EDT
* Data from AML patients with a flt3 mutation demonstrated vyxeos had a statistically significant improvement in induction response rate
